In the past three weeks, a flurry of licensing deals with Chinese biotechs were announced featuring AbbVie, AstraZeneca, ...

As AstraZeneca floods money into the U.S. market with a wide-ranging investment plan, the company has tapped an in-house executive to lead the surge. | Suarez will return to the U.S. as SVP and ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

It’s been more than ten years since the FDA signed off on the United States’ first biosimilar product, opening up what was ...

InflaRx had been pursuing development of vilobelimab in other indications beyond COVID, but the company’s hopes for the asset ...

Less than two weeks ago, Vanda scored an FDA approval for motion sickness pill Nereus. The decision came 15 months after the ...

Novo took its message to the people by setting up an exhibit at New York’s Grand Central Terminal. In a major thoroughfare at ...

Acuitas Therapeutics shelled out an undisclosed sum to acquire a majority stake in Montreal-based and privately held RNA Technologies & Therapeutics in a move to scale the latter’s operations around ...

Bayer has filed separate lawsuits against the creators of three COVID-19 vaccines, claiming they violated intellectual ...

Daiichi Sankyo is eying new horizons for its leukemia med Vanflyta, with Genesis Pharma signing on to commercialize the drug ...

The FDA is apparently not charmed by the mischievous “Lipid Lurkers” in an Esperion Therapeutics commercial for ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...